Clinical Trials

MyeloidOther hematologic neoplasmPlasma cell

21 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05987696 2026-02-11

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

2 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04898894 2026-01-26

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

37 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03709758 2026-01-16

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

50 enrolled

Leukemia, Myeloid, Acute

NCT05317403 2026-01-12

Venetoclax to Augment Epigenetic Modification and Chemotherapy

40 enrolled

Leukemia, Myeloid, Acute

NCT04220684 2026-01-09

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

19 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05342584 2026-01-08

Venetoclax AML

99 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT06001788 2025-12-03

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

171 enrolled

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05146739 2025-11-12

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

8 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT03900949 2025-10-28

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

21 enrolled

Leukemia, Myeloid, Acute

NCT03263936 2025-10-16

Epigenetic Reprogramming in Relapse/Refractory AML

37 enrolled 11 charts

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT05712278 2025-09-12

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

7 enrolled

Leukemia, Myeloid, Acute

NCT04891757 2025-07-10

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

144 enrolled

LymphoidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05521087 2025-06-22

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1 Withdrawn

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03813147 2025-04-13

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

12 enrolled 16 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02632708 2025-04-11

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

153 enrolled

Leukemia, Myeloid, Acute

NCT06313437 2025-03-27

Revumenib in Combination With 7+3 + Midostaurin in AML

22 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT02834390 2025-03-05

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

7 enrolled 16 charts

Neoplasms, Leukemia, Myeloid, Acute

NCT02038777 2025-02-26

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

48 enrolled 85 charts

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04250051 2025-01-13

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

2 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

61 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04526795 2024-12-12

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

LymphoidMyeloidOther hematologic neoplasm

19 enrolled

Blast Crisis, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05601466 2024-11-06

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

3 enrolled

Leukemia, Myeloid, Acute

NCT02236013 2024-11-05

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

80 enrolled

Leukemia, Myeloid, Acute

NCT04275518 2024-10-15

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02484391 2024-09-19

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Other hematologic neoplasmSarcoma

48 enrolled 13 charts

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02971397 2024-05-06

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

40 enrolled

Leukemia, Myeloid, Acute

NCT04196010 2023-12-28

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

13 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03904251 2023-11-18

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

13 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT03298984 2023-11-15

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

32 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT02957032 2023-10-10

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

30 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02649764 2023-10-04

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

15 enrolled

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05456269 2023-10-03

BISECT

Phase 1 Withdrawn

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02299518 2023-06-15

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

23 enrolled

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Phase 1 Withdrawn

Recurrence, Leukemia, Myeloid, Acute

NCT02891278 2023-04-12

Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

6 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT03194932 2023-02-14

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

62 enrolled

Leukemia, Myeloid, Acute

NCT05665114 2023-01-03

Natural Killer(NK) Cell Therapy in r/r AML

Phase 1 Unknown

18 enrolled

Leukemia, Myeloid, Acute

NCT04402723 2022-12-01

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

8 enrolled

Leukemia, Myeloid, Acute

NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

21 enrolled

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute

NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

24 enrolled